Autologous olfactory mucosal cell transplants in clinical spinal cord injury	1
Autologous olfactory mucosal cell transplants	1
clinical spinal cord injury	50
double-blinded trial in a canine translational model Nicolas Granger ,1	92
double-blinded trial	92
a canine translational model Nicolas Granger ,1	116
Helen Blamires ,1 Robin J. M. Franklin1 ,2	165
Helen Blamires	165
,1 Robin J. M. Franklin1 ,2	179
Nick D.	210
Jeffery1 1 Department	218
Veterinary Medicine	243
University	264
Cambridge , Cambridge , CB3 0ES , UK 2 Cambridge Stem Cell Institute	278
Cambridge , Cambridge , CB3 0ES	278
UK 2 Cambridge Stem Cell Institute	309
UK 2	309
Cambridge Stem Cell Institute	314
University of Cambridge , UK * Present address : School of Veterinary Sciences	345
University of Cambridge , UK * Present address	345
University of Cambridge , UK *	345
University	345
Cambridge , UK	359
Present address	374
School of Veterinary Sciences	391
School	391
Veterinary Sciences	401
University of Bristol	422
University	422
Bristol	436
Langford House	445
Langford	461
North Somerset	471
BS40 5DU	487
UK Correspondence to : Nick D. Jeffery	497
UK Correspondence to	497
UK Correspondence	497
Nick D. Jeffery	519
Department of Veterinary Clinical Sciences	536
Department	536
Veterinary Clinical Sciences	550
College of Veterinary Medicine	580
College	580
Veterinary Medicine	591
Iowa State University	612
1600 South 16th Street	635
1600	635
South 16th Street	640
Ames	659
IA 50011	665
USA	675
This study	681
an intervention	726
the laboratory to ameliorate the effects of experimental spinal cord injury	762
the effects of experimental spinal cord injury	791
the effects	791
experimental spinal cord injury	806
sufficient benefit	852
value	880
clinical cases	889
Intraspinal olfactory ensheathing cell transplantation	905
Intraspinal olfactory ensheathing	905
cell transplantation	939
locomotor outcome	969
spinal cord injury in ` proof of principle '	993
spinal cord injury	993
proof of principle	1016
proof	1016
principle	1025
experiments in rodents	1036
experiments	1036
rodents	1051
the possibility of efficacy	1071
the possibility	1071
efficacy	1090
human patients	1102
laboratory animal spinal cord injury	1127
laboratory animal	1127
spinal cord injury	1145
the inherent heterogeneity of clinical patient cohorts	1188
the inherent heterogeneity	1188
clinical patient cohorts	1218
all aspects	1252
their spinal cord function readily amenable to objective evaluation	1267
their spinal cord function	1267
objective evaluation	1314
we	1342
the effects	1354
intraspinal transplantation	1369
cells	1400
olfactory mucosal cultures	1419
a mean of ≈ 50 % olfactory ensheathing cells	1458
a mean	1458
≈ 50 % olfactory ensheathing cells	1468
a population of spinal cord	1505
a population	1505
spinal cord	1521
injured companion dogs	1533
many of the potential obstacles involved in transition from laboratory to clinic	1578
many	1578
the potential obstacles involved in transition from laboratory to clinic	1586
the potential obstacles	1586
transition	1622
laboratory	1638
clinic	1652
Dogs	1660
severe chronic thoracolumbar spinal cord injuries	1670
equivalent to ASIA grade ` A ' human patients at ≈ 12 months after injury	1721
equivalent to ASIA grade ` A ' human patients at ≈ 12 months	1721
ASIA grade	1735
` A	1746
human patients	1750
≈ 12 months	1768
injury	1785
a	1811
double-blinded clinical trial	1824
they	1863
intraspinal autologous cells	1901
olfactory mucosal cultures or injection of cell transport medium	1943
olfactory mucosal cultures	1943
injection of cell transport medium	1973
injection	1973
cell transport medium	1986
Recipients of olfactory mucosal cell transplants	2015
Recipients	2015
olfactory mucosal cell transplants	2029
significantly better fore	2071
hind coordination than those dogs receiving cell transport medium alone	2097
hind coordination	2097
those dogs receiving cell transport medium alone	2120
those dogs	2120
cell transport medium	2141
There	2170
no significant differences	2181
outcome between treatment groups in measures of long tract functionality	2211
outcome	2211
treatment groups in measures of long tract functionality	2227
treatment groups	2227
measures of long tract functionality	2247
measures	2247
long tract functionality	2259
We	2285
intraspinal olfactory mucosal cell transplantation	2302
communication	2362
the damaged region of the injured spinal cord	2383
the damaged region	2383
the injured spinal cord	2405
chronically injured individuals	2438
we	2480
no evidence for concomitant improvement in long tract function	2488
no evidence	2488
concomitant improvement in long tract function	2504
concomitant improvement	2504
long tract function	2531
Introduction Spinal cord injury	2553
Introduction	2553
Spinal cord injury	2566
a devastating impact	2589
the emotional and physical well-being of affected individuals	2613
the emotional and physical well-being	2613
affected individuals	2654
a substantial financial burden on providers of long-term health care	2687
a substantial financial burden	2687
providers of long-term health care	2721
providers	2721
long-term health care	2734
-LRB- National Spinal Cord Injury Center , https://www.nscisc.uab	2756
edu	2817
Many interventions	2824
beneficial effects on outcome	2861
beneficial effects	2861
outcome	2883
spinal cord injury in ` proof of principle ' experiments in laboratory animals	2897
spinal cord injury	2897
` proof of principle ' experiments in laboratory animals	2919
` proof of principle '	2919
proof	2920
principle	2929
experiments in laboratory animals	2940
experiments	2940
laboratory animals	2955
pharmacological and biological agents	2985
Kwon	3024
et al. , 2011a , b ; Tetzlaff et al. , 2011	3029
et al.	3029
2011a , b ; Tetzlaff et al.	3037
2011a , b	3037
2011a	3037
b	3044
Tetzlaff et al.	3047
Tetzlaff	3047
et al.	3056
2011	3064
training -LRB- Edgerton et al. , 2008 -RRB-	3071
training	3071
Edgerton	3081
et al. , 2008	3090
et al.	3090
2008	3098
rehabilitation -LRB- Wang et al. , 2011 -RRB- strategies	3108
rehabilitation	3108
Wang	3124
et al. , 2011	3129
et al.	3129
2011	3137
strategies	3143
these	3158
intraspinal transplantation of olfactory ensheathing cell	3165
intraspinal transplantation	3165
olfactory ensheathing cell	3196
one	3226
the most promising	3233
Ibrahim	3253
et al. , 2006 ; Ramon-Cueto and Mun˜ oz-Quiles , 2011	3261
et al.	3261
2006 ; Ramon-Cueto and Mun˜ oz-Quiles	3269
2006	3269
Ramon-Cueto and Mun˜ oz-Quiles	3275
Ramon-Cueto	3275
Mun˜ oz-Quiles	3291
2011	3307
experimental models of spinal cord injury	3332
experimental models	3332
spinal cord injury	3355
new therapies	3398
success in laboratory animals	3413
success	3413
laboratory animals	3424
benefit for patients	3479
benefit	3479
patients	3491
the many differences between models and clinical disease	3511
the many differences	3511
models and clinical disease	3540
models	3540
clinical disease	3551
most human patients	3578
candidates for transplantation therapy	3606
candidates	3606
transplantation therapy	3621
a variable , and often considerable , delay from initial injury	3651
a variable , and often considerable , delay	3651
initial injury	3698
there	3724
far greater heterogeneity	3733
even a	3766
patient cohort	3782
a typical experimental group	3809
purpose-bred rodents	3841
similar age , mass , injury severity and genetic background	3865
similar age	3865
mass	3878
injury severity	3884
genetic background	3904
obscure detection of the effect of interest	3943
obscure detection	3943
the effect of interest	3964
the effect	3964
interest	3978
the magnitude of the treatment effect , even if statistically detectable ,	3997
the magnitude	3997
the treatment effect	4014
sufficient magnitude	4084
patients	4136
The potential of these factors to obstruct effective translation	4146
The potential	4146
these factors	4163
effective translation	4189
attention	4244
other fields	4257
medicine -LRB- Lowenstein and Castro , 2009 ; Begley and Ellis , 2012 -RRB-	4273
medicine	4273
Lowenstein and Castro	4283
Lowenstein	4283
Castro	4298
2009 ; Begley and Ellis , 2012	4306
2009	4306
Begley and Ellis , 2012	4312
Begley and Ellis	4312
2012	4330
conventional laboratory models	4374
Spinal cord injury	4406
a common condition in companion dogs	4428
a common condition	4428
companion dogs	4450
the high prevalence of intervertebral disc degeneration	4476
the high prevalence	4476
intervertebral disc degeneration	4499
acute nuclear herniation	4536
Priester , 1976 ; Fluehmann et al. , 2006	4562
Priester	4562
1976 ; Fluehmann et al.	4572
1976	4572
Fluehmann et al.	4578
Fluehmann	4578
et al.	4588
2006	4596
a large population	4616
the effects of putative therapeutic interventions	4644
the effects	4644
putative therapeutic interventions	4659
These dogs	4709
specialist veterinarians	4749
similar methods	4780
those currently available in human patients with spinal cord injury	4799
human patients with spinal cord	4828
human patients	4828
spinal cord	4848
a clinical trial of a putative therapy for spinal cord injury in dogs	4879
a clinical trial	4879
a putative therapy for spinal cord injury in dogs	4899
a putative therapy	4899
spinal cord injury in dogs	4922
spinal cord injury	4922
dogs	4944
we	4950
a series of kinematic outcome measures	4968
a series	4968
kinematic outcome measures	4980
the effect	5031
an intervention on locomotor function -LRB- Hamilton et al. , 2007 , 2008 -RRB-	5045
an intervention	5045
locomotor function -LRB- Hamilton et al. , 2007 , 2008 -RRB-	5064
locomotor function	5064
Hamilton	5084
et al. , 2007 , 2008	5093
et al.	5093
2007	5101
2008	5107
Objective quantification of gait coordination in dogs	5114
Objective quantification	5114
gait coordination in dogs	5142
gait coordination	5142
dogs	5163
their quadrupedal gait	5186
it	5217
analysis	5227
the temporal relationships of motion between thoracic and pelvic limbs	5239
the temporal relationships	5239
motion between thoracic and pelvic limbs	5269
motion	5269
thoracic and pelvic limbs	5284
This study	5311
the first double-blinded randomized trial	5334
the efficacy	5379
intraspinal transplants	5395
cells	5422
olfactory mucosa cell cultures	5441
50	5485
%	5487
p75 + olfactory ensheathing cells	5489
p75	5489
olfactory ensheathing cells	5495
clinical spinal cord injury	5527
a means	5576
potential obstacles	5595
a putative therapy	5639
laboratory	5663
clinic	5677
The subjects	5685
a sample	5703
dogs	5715
the chronic phase	5723
the injury	5744
the large population	5770
client-owned -LRB- i.e. non-experimental -RRB- dogs	5794
i.e. non-experimental	5808
i.e.	5808
non-experimental	5813
previously sustained severe acute spinal cord injury	5845
This phase	5899
their established poor prognosis -LRB- Olby et al. , 2003 -RRB-	5929
their established poor prognosis	5929
Olby	5963
et al. , 2003	5968
et al.	5968
2003	5976
the efficiency of detection of benefits -LRB- Fawcett et al. , 2007 -RRB-	6000
the efficiency	6000
detection of benefits -LRB- Fawcett et al. , 2007 -RRB-	6018
detection	6018
benefits -LRB- Fawcett et al. , 2007 -RRB-	6031
benefits	6031
Fawcett	6041
et al. , 2007	6049
et al.	6049
2007	6057
The effects of intraspinal autologous olfactory mucosal cell transplantation	6064
The effects	6064
intraspinal autologous olfactory mucosal cell transplantation	6079
injection of cell transport medium	6160
injection	6160
cell transport medium	6173
a primary outcome measure of forelimb	6207
a primary outcome measure	6207
forelimb	6236
hindlimb coordination	6245
detailed objective analysis of locomotor coordination	6281
detailed objective analysis	6281
locomotor coordination	6312
a series of secondary outcome measures	6336
a series	6336
secondary outcome measures	6348
the aim	6400
the mechanisms	6423
olfactory mucosal cell transplants	6447
an effect	6494
Materials	6506
methods Study design	6520
methods	6520
Study design	6528
canine subjects Candidate companion dogs with severe spinal cord injury	6545
canine subjects	6545
Candidate companion dogs with severe spinal cord injury	6561
Candidate companion dogs	6561
severe spinal cord injury	6591
this study between October 2008	6636
this study	6636
October 2008	6655
March 2011	6672
professional contacts	6691
presentations at veterinary conferences and notices	6714
presentations	6714
veterinary conferences and notices	6731
websites	6769
inclusion	6783
we	6794
dogs	6812
< 20 kg	6830
<	6830
20 kg	6831
an acute spinal cord injury located between T10 and L4 spinal cord	6847
T10 and L4	6891
the canine spinal cord	6915
seven lumbar segments	6942
≈ L5 vertebra	6982
conscious pain perception	7022
i.e.	7049
no behavioural response to intensely noxious stimuli	7054
no behavioural response	7054
intensely noxious stimuli	7081
the hindquarters	7118
the ability	7140
the hindlimbs	7170
i.e. equivalent	7185
i.e.	7185
thoracic ASIA	7204
Spinal Injury Association	7228
` A	7255
human patients	7259
at least 3 months	7277
the initial injury	7301
Available literature -LRB- Olby et al. , 2003 ; Fawcett et al. , 2007 -RRB-	7321
Available literature	7321
Olby	7343
et al. , 2003 ; Fawcett et al. , 2007	7348
et al.	7348
2003 ; Fawcett et al.	7356
2003	7356
Fawcett et al.	7362
Fawcett	7362
et al.	7370
2007	7378
this time delay	7398
12 months	7432
injury in human patients	7448
injury	7448
human patients	7458
We	7474
the term ` ability	7481
some dogs	7525
reflex hindlimb	7548
treadmill	7580
overground walking	7603
complete thoracolumbar spinal cord injury -LRB- Handa et al. , 1986 -RRB-	7628
complete thoracolumbar spinal cord injury	7628
Handa	7671
et al. , 1986	7677
et al.	7677
1986	7685
Trial exclusion criteria	7692
intercurrent disease	7722
constant medication	7753
ill health with a prognosis for survival of < 12 months	7786
ill health	7786
a prognosis for survival of < 12 months	7802
a prognosis	7802
survival of < 12 months	7818
survival	7818
< 12 months	7830
<	7830
12 months	7831
orthopaedic disease that would preclude accurate locomotor assessment	7842
orthopaedic disease	7842
accurate locomotor assessment	7882
unsuitable temperament	7916
The study	7940
the regulations	7970
the Veterinary Surgeons	8003
Act	8027
1966	8032
the interventions	8044
therapeutic intent	8078
we	8098
previous data suggesting an immediate effect after intraspinal injections	8105
previous data	8105
an immediate effect	8130
intraspinal injections	8156
the study protocol	8185
the Royal College of Veterinary Surgeons	8233
the Royal College	8233
Veterinary Surgeons	8254
the Ethical Review Committee	8278
the Department of Veterinary Medicine , University of Cambridge	8310
the Department	8310
Veterinary Medicine , University of Cambridge	8328
Veterinary Medicine	8328
University of Cambridge	8349
University	8349
Cambridge	8363
the study	8380
The owner of each dog	8407
The owner	8407
each dog	8420
written consent	8434
the procedures	8453
the nature of the study , the comparator groups and the possibility	8492
the nature	8492
the study , the comparator groups and the possibility	8506
the study	8506
the comparator groups	8517
the possibility	8543
neither intervention would have a beneficial effect ; our previous study	8564
neither intervention	8564
a beneficial effect ; our previous study	8596
a beneficial effect	8596
our previous study	8617
transplantation of olfactory bulb-derived cell cultures	8655
transplantation	8655
olfactory bulb-derived cell cultures	8674
dogs -LRB- Jeffery et al. , 2005 -RRB-	8723
dogs	8723
Jeffery	8729
et al. , 2005	8737
et al.	8737
2005	8745
Randomization and masking	8752
The study	8778
CONSORT guidelines -LRB- Consolidated Standards of Reporting Trials -RRB-	8815
CONSORT guidelines	8815
Consolidated Standards of Reporting Trials	8835
Consolidated Standards	8835
Reporting Trials	8861
Consort	8881
statement , http : /	8889
statement	8889
http	8900
/	8905
a detailed definition	8965
primary and secondary outcome measures before trial onset	8990
primary and secondary outcome measures	8990
trial onset	9036
subject flow through the study	9049
subject flow	9049
the study	9070
Fig. 1	9098
Consecutive patients	9106
all of the inclusion criteria and none of the exclusion criteria	9135
all of the inclusion criteria	9135
all	9135
the inclusion criteria	9142
none of the exclusion criteria	9169
none	9169
the exclusion criteria	9177
the study	9217
preparation of the autologous cell culture for transplantation	9234
preparation	9234
the autologous cell culture for transplantation	9249
the autologous cell culture	9249
transplantation	9281
each dog	9298
spinal needles	9326
the lesion site -LRB- see later in the text -RRB-	9358
the lesion site	9358
the text	9388
intraspinal injection	9434
either an olfactory mucosal cell suspension or cell transport medium	9459
an olfactory mucosal cell suspension	9466
cell transport medium	9506
Randomization	9535
a sealed opaque envelope	9578
each containing the word ` cells ' or ` medium '	9604
each	9604
the word ` cells ' or ` medium '	9620
word ` cells '	9624
` medium '	9640
Three blocks of 18 envelopes	9650
Three blocks	9650
18 envelopes	9666
only two	9703
time and financial constraints	9732
each	9765
which contained 12 envelopes containing ` cells ' and six containing ` medium '	9773
12 envelopes	9789
cells	9814
six containing ` medium '	9825
six	9825
medium	9841
the envelopes	9865
hand	9896
a locked drawer	9913
access	9934
the unblinded investigator	9959
N.D.J.	9987
the different treatments	10012
We	10038
a 2:1 ratio	10047
we	10067
the cell transplant	10087
effect on only a proportion of transplanted animals	10118
effect	10118
only a proportion of transplanted animals	10128
only a proportion	10128
transplanted animals	10149
Owners	10171
treatment allocation	10194
the end of the study period -LRB- 6 months -RRB-	10221
the end	10221
the study period -LRB- 6 months -RRB-	10232
the study period	10232
6 months	10250
the clinician and technician responsible for recording the outcome measures	10265
the clinician and technician	10265
the outcome measures	10320
intervention allocation	10357
completion of data analysis	10387
completion	10387
data analysis	10401
Procedures	10416
entry to the study	10430
entry	10430
the study	10439
each dog	10450
a specialist veterinary neurologist -LRB- N.D.J. or N.G. -RRB-	10475
a specialist veterinary neurologist	10475
N.D.J. or N.G.	10512
N.D.J.	10512
N.G.	10522
standard T1 - and T2-weighted magnetic resonance	10547
standard T1	10547
T2-weighted magnetic resonance	10564
imaging scanning -LRB- 0.2 Tesla Vet MR , Esaote -RRB-	10595
imaging scanning	10595
0.2 Tesla Vet MR , Esaote	10613
0.2 Tesla Vet MR	10613
Esaote	10631
the affected region , treadmill gait recording -LRB- see later in the text -RRB-	10642
the affected region , treadmill gait recording	10642
the text	10702
recording of somatosensory	10713
recording	10713
somatosensory	10726
transcranial magnetic motor-evoked potentials and urodynamics assessment	10745
receipt of the randomly allocated treatment -LRB- given at time = 0 -RRB-	10825
receipt	10825
the randomly allocated treatment -LRB- given at time = 0 -RRB-	10836
the randomly allocated treatment	10836
time = 0	10879
time	10879
0	10886
Gait analysis Gait analysis	10890
Gait analysis	10890
Gait analysis	10904
as previously described -LRB- Hamilton et al. , 2007 , 2008 -RRB-	10934
as previously described	10934
as previously	10934
Hamilton	10959
et al. , 2007 , 2008	10968
et al.	10968
2007	10976
2008	10982
dogs	10998
a treadmill	11013
retroflective markers	11030
prominent bone landmarks on forelimbs and hindlimbs	11062
prominent bone landmarks	11062
forelimbs and hindlimbs	11090
recordings	11120
limb motion	11144
gait analysis equipment -LRB- Qualisys -RRB-	11162
gait analysis equipment	11162
Qualisys	11187
Digital data	11198
MATLAB software	11239
extract points of interest	11258
extract points	11258
interest	11276
i	11299
coordination	11302
hindlimb and forelimb movements	11323
the sagittal plane	11358
` fore -- hind coordination '	11390
fore	11391
hind coordination	11396
connectivity	11437
the lesion site	11457
ii	11479
reproducibility of hindlimb paw placement in the lateral plane	11483
reproducibility	11483
hindlimb paw placement in the lateral plane	11502
hindlimb paw placement	11502
the lateral plane	11528
the coefficient of variation of the distance between hindlimb paws	11562
the coefficient	11562
variation of the distance between hindlimb paws	11581
variation	11581
the distance between hindlimb paws	11594
the distance	11594
hindlimb paws	11615
lateral stability	11643
coordination between hindlimb paws and body position	11684
coordination	11684
hindlimb paws and body position	11705
hindlimb paws	11705
body position	11723
it	11746
a specific treadmill speed	11769
the reflex	11826
rhythm of the hindlimbs	11846
rhythm	11846
the hindlimbs	11856
different treadmill speeds	11904
the voluntary	11955
rhythm of the forelimbs	11978
rhythm	11978
the forelimbs	11988
we	12002
locomotion	12014
two speeds	12028
analysis of fore -- hind coordination	12044
analysis of fore	12044
analysis	12044
fore	12056
hind coordination	12061
we	12080
only the data	12088
the speed	12107
there	12126
worse coordination	12136
the potential for ` entrainment '	12176
the potential	12176
` entrainment '	12194
inaccurate data	12219
The calculated score for comparison	12237
The calculated score	12237
comparison	12262
the temporal relationship	12284
each hind paw placement	12318
the contralateral fore paw	12354
treadmill stepping	12388
treadmill	12388
each limb pair	12408
the mean score determined and entered into statistical analysis	12448
the mean score	12448
statistical analysis	12491
recovery from incomplete spinal cord injury in dogs	12520
recovery	12520
incomplete spinal cord injury in dogs	12534
incomplete spinal cord injury	12534
dogs	12567
clinically observable improvement in locomotion	12573
clinically observable improvement	12573
locomotion	12610
gradual recovery of both fore	12638
gradual recovery	12638
both fore	12658
hind coordination and lateral stability	12668
normal values -LRB- Jeffery et al. , 2011 -RRB-	12716
normal values	12716
Jeffery	12731
et al. , 2011	12739
et al.	12739
2011	12747
Somatosensory-evoked potentials Somatosensory-evoked potentials	12754
Somatosensory-evoked potentials	12754
Somatosensory-evoked potentials	12786
both hindlimbs of each dog	12837
both hindlimbs	12837
each dog	12855
sedation	12870
standard techniques -LRB- Poncelet et al. , 1993 -RRB-	12885
standard techniques	12885
Poncelet	12906
et al. , 1993	12915
et al.	12915
1993	12923
stimulation of the tibial nerve at the hock -LRB- ankle -RRB-	12932
stimulation	12932
the tibial nerve at the hock -LRB- ankle -RRB-	12947
the tibial nerve	12947
the hock -LRB- ankle -RRB-	12967
the hock	12967
ankle	12977
the contralateral sensory cortex	13003
signal averaging -LRB- 256 sweeps -RRB-	13043
signal averaging	13043
256 sweeps	13061
Transcranial magnetic motor-evoked potentials	13074
Transcranial magnetic motor-evoked potentials	13120
both hindlimbs of each dog	13185
both hindlimbs	13185
each dog	13203
sedation	13218
established techniques	13233
Sylvestre	13257
et al. , 1993 ; Da Costa et al. , 2006	13267
et al.	13267
1993 ; Da Costa et al.	13275
1993	13275
Da Costa et al.	13281
Da Costa	13281
et al.	13290
2006	13298
the single coil stimulator -LRB- Magstim 200 -RRB-	13305
the single coil stimulator	13305
Magstim 200	13333
the motor cortex	13366
the cranial tibial muscle	13420
Urodynamics	13447
sedation	13467
bladder cystometry with combined rectal pressure measurement recordings	13477
bladder cystometry	13477
combined rectal pressure measurement recordings	13501
conventional urodynamic equipment -LRB- Life-Tech , Urolab Primus 6 -RRB-	13565
conventional urodynamic equipment	13565
Life-Tech , Urolab Primus 6	13600
Life-Tech	13600
Urolab Primus 6	13611
Compliance	13629
the International Continence Society -LRB- Abrams et al. , 2003 -RRB-	13667
the International Continence Society	13667
Abrams	13705
et al. , 2003	13712
et al.	13712
2003	13720
the change	13729
volume	13743
the change in pressure at full bladder physiological capacity or first leak	13761
pressure at full bladder	13775
pressure	13775
full bladder	13787
Cell harvest and culture	13838
initial gait	13869
electrophysiological and urodynamic recordings	13883
each dog	13946
general anaesthesia	13965
the left frontal sinus of the skull	13989
the left frontal sinus	13989
the skull	14015
the olfactory mucosa	14058
the ostium of the frontal sinus	14092
the ostium	14092
the frontal sinus	14106
the caudal nasal cavity -LRB- Skinner et al. , 2005 -RRB-	14128
the caudal nasal cavity	14128
Skinner	14153
et al. , 2005	14161
et al.	14161
2005	14169
The small fragments of obtained olfactory mucosa	14176
The small fragments	14176
obtained olfactory mucosa	14199
20 ml of Leibovitz sterile medium -LRB- L15 -RRB-	14240
20 ml	14240
Leibovitz sterile medium -LRB- L15 -RRB-	14249
Leibovitz sterile medium	14249
Leibovitz	14249
L15	14275
a Petri dish , pre-cooled at 4 °C ,	14283
a Petri dish	14283
4 °C	14311
ice	14324
the operating room	14349
the laboratory to be processed	14371
The mucosal biopsies	14403
ice	14442
cartilage fragments , blood vessels , connective tissue and non-olfactory mucosa	14481
cartilage fragments	14481
blood vessels	14502
connective tissue	14517
non-olfactory mucosa	14539
The remaining olfactory mucosa	14561
a scalpel blade for 1 min	14614
a scalpel blade	14614
1 min	14634
15 min	14660
37 °C	14670
1 ml of Dulbecco 's modified Eagle medium containing 0.25 mg of 112	14679
1 ml	14679
Dulbecco 's modified Eagle medium containing 0.25 mg of 112	14687
Dulbecco 's modified Eagle medium	14687
Dulbecco 's	14687
0.25 mg of 112	14731
0.25 mg	14731
112	14741
U collagenase	14745
incubation	14766
1 ml	14778
Dulbecco 's modified Eagle medium containing 0.5 mg of bovine pancreas DNase	14786
Dulbecco 's modified Eagle medium	14786
Dulbecco 's	14786
0.5 mg of bovine pancreas DNase	14830
0.5 mg	14830
bovine pancreas DNase	14839
the tissue	14875
1 min	14905
glass pipettes	14919
40µm filter	14945
10 ml	14969
Dulbecco 's modified Eagle medium containing 10 % foetal bovine serum	14975
Dulbecco 's modified Eagle medium containing 10 %	14975
Dulbecco 's modified Eagle medium	14975
Dulbecco 's	14975
10 %	15019
foetal bovine serum	15023
1000 rpm , 5 min	15060
1000 rpm	15060
5 min	15070
The pellet	15078
fresh culture medium	15108
Dulbecco 's modified Eagle medium	15140
Dulbecco 's	15140
10 % foetal bovine serum	15174
2 µM forskolin	15199
dimethyl sulphoxide	15217
20 ng/ml neuregulin 1 and 10 mg/ml gentamicin	15238
20 ng/ml neuregulin	15238
1 and 10 mg/ml gentamicin	15258
10 000 to 50 000 viable cells/ml	15296
10 000	15296
50 000 viable cells/ml	15306
poly-L-lysine	15335
coated 25-cm2 flasks	15349
Cultures	15371
37 °C in 5 % carbon dioxide	15399
37 °C	15399
5 % carbon dioxide	15407
initial plating	15432
cultures	15449
5 -- 7 days	15479
5	15479
7 days	15481
cell adhesion	15497
one half of the growth medium	15524
one half	15524
the growth medium	15536
every 3 days	15566
cell passaging	15584
trypsin solution -LRB- 2.5 % in PBS -RRB-	15600
trypsin solution	15600
2.5 % in PBS	15618
2.5 %	15618
PBS	15626
the cells	15650
Cells of interest	15661
Cells	15661
interest	15670
detachment of elongated cells under a microscope	15706
detachment	15706
cells	15730
a microscope	15742
the trypsin	15768
this time point -LRB- usually 52 min -RRB-	15783
this time point	15783
52 min	15808
further detachment	15827
contaminant cells -LRB- i.e. differential trypsinization -RRB-	15849
contaminant cells	15849
i.e. differential trypsinization	15868
i.e.	15868
differential trypsinization	15873
The obtained cells	15903
new uncoated 25-cm2 flasks using the medium described earlier	15937
new uncoated 25-cm2 flasks	15937
the medium described earlier	15970
the medium	15970
the uncoated flasks	16017
24 h	16051
cells , as described previously -LRB- Ito et al. , 2008 -RRB-	16107
cells , as described previously	16107
cells	16107
Ito	16139
et al. , 2008	16143
et al.	16143
2008	16151
The supernatant	16158
new poly-L-lysine -- coated 25-cm2 flasks	16188
new poly-L-lysine	16188
coated 25-cm2 flasks	16206
the first 7 -- 10 days in culture	16234
the first 7	16234
10 days in culture	16246
10 days	16246
culture	16257
the foetal bovine serum concentration	16266
10 % to 2.5 %	16331
7 days	16348
cellular growth	16369
a sufficient number of cells	16391
a sufficient number	16391
cells	16414
the cells	16433
larger -LRB- 75 cm2 and T175 cm2 -RRB- flasks	16458
75 cm2 and T175 cm2	16466
75 cm2	16466
T175 cm2	16477
the day of transplantation	16498
the day	16498
transplantation	16509
the cell population	16526
the proportion of p75 + cells and the total population number	16572
the proportion	16572
p75 + cells and the total population number	16590
p75 + cells	16590
the total population number	16606
We	16635
a population of at least 5 x 10 ^ 6 cells	16655
a population of at least 5	16655
a population	16655
at least 5	16671
10 ^ 6 cells	16684
10	16684
6 cells	16687
at least 2.5	16707
10 ^ 6 p75	16722
10	16722
6 p75	16725
cells	16733
i.e.	16740
those previously	16745
olfactory ensheathing cells in nasal mucosal cultures	16776
olfactory ensheathing cells	16776
nasal mucosal cultures	16807
Ito	16832
et al. , 2008	16836
et al.	16836
2008	16844
the time of transplantation	16853
the time	16853
transplantation	16865
the required number of cells	16887
the required number	16887
cells	16910
transplantation	16930
3 and 5 weeks after harvesting	16955
3 and 5 weeks	16955
harvesting	16975
each dog	16988
fluoroscopy	17037
an image intensifier	17056
a resolution of 441 pixels/cm	17082
a resolution	17082
441 pixels/cm	17098
the centre of the screen	17115
the centre	17115
the screen	17129
placement of 20 -- 22-gauge 90-mm long spinal needles	17150
placement of 20	17150
placement	17150
20	17163
22-gauge 90-mm long spinal needles	17166
the interarcuate ligaments between the vertebral laminae	17224
the interarcuate ligaments	17224
the vertebral laminae	17259
the affected region of the spinal cord identified previously by MRI	17286
the affected region	17286
the spinal cord identified previously by MRI	17309
the spinal cord	17309
MRI	17350
each dog	17359
three needles	17369
one	17396
the vertebrae	17408
the epicentre of the lesion and one each	17432
the epicentre of the lesion	17432
the epicentre	17432
the lesion	17449
one each	17464
one	17464
each	17468
the neighbouring intervertebral spaces	17476
The needles	17516
the spinal cord parenchyma	17550
the ventral aspect of the vertebral canal	17586
the ventral aspect	17586
the vertebral canal	17608
this position	17632
fluoroscopy	17668
cerebrospinal fluid	17694
the needle hub	17728
some cases	17752
injections of radiographic contrast agent	17764
injections	17764
radiographic contrast agent	17778
the vertebral canal	17856
their correct location	17896
the vertebral canal	17926
the needles	17947
a few millimetres	17974
the needle bevel	18000
the centre of the vertebral canal	18038
the centre	18038
the vertebral canal	18052
the spinal cord parenchyma	18094
this stage	18126
dogs	18138
a 2:1 ratio of olfactory mucosal cell : medium alone	18163
a 2:1 ratio	18163
olfactory mucosal cell	18178
medium alone	18202
olfactory mucosal cell in cell transplant medium	18234
olfactory mucosal cell	18234
cell transplant medium	18260
the same volume of cell transport medium	18286
the same volume	18286
cell transport medium	18305
the parenchyma of the spinal cord	18357
the parenchyma	18357
the spinal cord	18375
The injection volume	18392
400 ml	18417
total	18427
a period of ≈ 5 min	18449
a period	18449
≈ 5 min	18461
200 ml injected at the epicentre	18469
200 ml	18469
the epicentre	18488
two boluses	18516
100 µl with the needle bevel	18529
100 µl	18529
the needle bevel	18541
100 µl with the needle bevel	18581
100 µl	18581
the needle bevel	18593
a single bolus of 100 µl at each neighbouring space	18634
a single bolus	18634
100 µl at each neighbouring space	18652
100 µl	18652
each neighbouring space	18662
the needle bevel	18692
the epicentre	18726
recovery	18744
each dog	18754
routine analgesia	18772
possible adverse effects for 24 h	18811
possible adverse effects	18811
24 h	18840
the owner 's care	18865
the owner 's	18865
Outcome measure assessment Each dog	18883
Outcome measure assessment	18883
Each dog	18910
1-monthly intervals for clinical neurological examination	18935
1-monthly intervals	18935
clinical neurological examination	18959
reassessment of locomotor performance	18997
reassessment	18997
locomotor performance	19013
the treadmill	19038
somatosensory-evoked potential	19053
transcranial magnetic motor-evoked potential recording	19088
Urodynamic assessments	19144
1 , 3 and 6	19180
months	19191
spinal cord injection	19204
Statistical analysis Pre-study power calculations	19227
responses in a Phase	19286
responses	19286
a Phase	19299
I trial -LRB- Jeffery et al. , 2005 -RRB-	19307
I trial	19307
Jeffery	19316
et al. , 2005	19324
et al.	19324
2005	19332
the need	19348
54 dogs	19361
total	19372
25 % improvement	19389
a set value	19408
the olfactory mucosal cell group	19423
a 0 % improvement in the control group	19463
a 0 % improvement	19463
the control group	19483
80 % power and P	19504
= 0.05	19520
a projected n = 48	19537
a projected n	19537
48	19553
Correction for the 2:1 randomization ratio	19557
Correction	19557
the 2:1 randomization ratio	19572
the need	19610
54 dogs	19623
total	19634
we	19655
numerical measurements of locomotor coordination and analysis	19666
numerical measurements	19666
locomotor coordination and analysis	19692
multivariable linear regression	19731
analytical efficiency	19780
all of the repeated-measures data	19806
all	19806
the repeated-measures data	19813
correction	19860
effect modifiers , confounders and covariates	19875
importantly here , the baseline values	19921
importantly here	19921
the baseline values	19939
Our pre-specified primary outcome measure	19985
a summary of fore	20031
a summary	20031
fore	20044
hind coordination	20049
the mean	20079
the score	20091
the ` cumulative lag ' between each hindlimb/contralateral forelimb pair	20113
the ` cumulative lag '	20113
each hindlimb/contralateral forelimb pair	20142
Data	20185
distributions	20236
Statistical analysis	20251
group	20294
olfactory mucosal cell transplantation versus medium injection	20301
olfactory mucosal cell transplantation	20301
medium injection	20347
visit -LRB- time -RRB-	20375
visit	20375
time	20382
variables	20391
a random effects model	20404
multivariable linear regression analysis	20427
cross-sectional time series data in Stata 11	20472
cross-sectional time series data	20472
Stata 11	20508
command ` xtreg '	20518
pre-intervention values	20553
their inclusion as a covariate -LRB- i.e. analysis of covariance -RRB-	20580
their inclusion	20580
a covariate -LRB- i.e. analysis of covariance -RRB-	20599
a covariate	20599
i.e. analysis of covariance	20612
i.e.	20612
analysis of covariance	20617
analysis	20617
covariance	20629
A two-sided P < 0.05	20642
A two-sided P <	20642
A two-sided P	20642
<	20655
0.05	20656
evidence	20674
the null hypothesis	20693
Pre-specified secondary outcome measures	20714
lateral stability during treadmill walking -LRB- Hamilton et al. , 2008 -RRB-	20760
lateral stability	20760
treadmill walking	20785
Hamilton	20804
et al. , 2008	20813
et al.	20813
2008	20821
somatosensory-evoked potential	20828
transcranial magnetic motor	20860
potential and bladder compliance	20895
Use of a kinematic variable as the primary outcome	20929
Use	20929
a kinematic variable as the primary outcome	20936
a kinematic variable	20936
the primary outcome	20960
objective data	20989
rigorous quantitative analysis	21015
a sense of value of the effect in treated cases	21084
a sense	21084
value of the effect in treated cases	21095
value	21095
the effect in treated cases	21104
the effect	21104
treated cases	21118
This	21133
analysis	21163
the relationship between intervention effect	21175
the relationship	21175
intervention effect	21200
the ` minimal important clinical difference ' or similar score-based schemes	21224
the ` minimal important clinical difference '	21224
similar score-based schemes	21271
Such schemes	21300
quality-of-life instruments	21345
they	21381
a subjective impression	21393
the objectively measured outcome	21420
this	21458
them	21471
non-verbal species	21491
distribution-based methods -LRB- Wyrwich and Wolinshy , 2000 -RRB-	21520
distribution-based methods	21520
Wyrwich and Wolinshy	21548
2000	21570
we	21598
the magnitude	21612
the effect	21629
groups -LRB- δ -RRB- using the formula δ = m2-m1 / σ1 ;	21650
groups -LRB- δ -RRB-	21650
groups	21650
δ	21658
the formula δ = m2-m1	21667
σ1	21689
m2 and m1	21699
the mean values	21713
coordination score in the two groups at study termination and Ψδ	21732
coordination score	21732
the two groups at study termination and Ψδ	21754
the two groups	21754
study termination and Ψδ	21772
the standard deviation -LRB- SD -RRB- of the whole sample population at baseline	21800
the standard deviation -LRB- SD -RRB-	21800
the standard deviation	21800
SD	21824
the whole sample population at baseline	21831
the whole sample population	21831
baseline	21862
cell transplant recipients	21884
we	21912
the relationship between functional recovery	21924
the relationship	21924
functional recovery	21949
the proportion	21973
p75 + cells -LRB- assumed to be olfactory ensheathing cells -RRB-	21991
p75 + cells	21991
olfactory ensheathing cells	22018
the transplanted culture	22050
regression analysis	22081
pre-transplant score	22124
inclusion as a covariate	22148
inclusion	22148
a covariate	22161
Results	22175
Table 1 Baseline animal data	22183
Table	22183
1 Baseline animal data	22189
Table	22213
2 Baseline values for outcome measures	22219
2 Baseline values	22219
outcome measures	22241
Table 3 Adverse events Figure 1 Flow chart	22259
patient recruitment , assessment and follow-up	22316
patient recruitment	22316
assessment	22337
follow-up	22352
OMC = olfactory mucosal cell .	22363
OMC	22363
= olfactory mucosal cell	22367
Figure 2 Flow chart to illustrate trial design .	22394
Figure 2 Flow chart	22394
trial design	22428
-LRB- A -RRB- Trial dogs	22442
-LRB- A -RRB-	22442
Trial dogs	22446
the population	22477
companion dogs	22495
severe spinal cord injury at least 3 months	22528
severe spinal cord injury	22528
at least 3 months	22554
behavioural evidence of pain perception	22604
behavioural evidence	22604
pain perception	22628
the hindlimbs or voluntary hindlimb locomotor function or urinary continence	22649
the hindlimbs	22649
voluntary hindlimb locomotor function or urinary continence	22666
They	22727
olfactory mucosal cells -LRB- OMCs -RRB- or cell transport medium	22767
olfactory mucosal cells	22767
OMCs	22792
cell transport medium	22801
a 2:1 ratio	22832
-LRB- B -RRB- Olfactory mucosa	22845
B	22846
each dog and olfactory mucosal cells	22885
each dog	22885
olfactory mucosal cells	22898
culture	22941
≈ 3 weeks	22953
a total population of ≈ 5 x	22974
a total population	22974
≈ 5 x	22996
10 ^ 6 cells	23001
10 ^	23001
6 cells	23004
50 %	23024
olfactory ensheathing cells -LRB- defined as p75 + by immunocytochemistry -RRB-	23028
olfactory ensheathing cells	23028
p75 +	23068
p75	23068
+	23072
immunocytochemistry	23077
transplantation	23105
values stated here	23121
values	23121
mean ± SEM of the cell population among all 34 dogs	23144
mean ± SEM	23144
the cell population among all 34 dogs	23158
the cell population	23158
all 34 dogs	23184
Each dog	23201
an intraspinal transplant	23219
either autologous olfactory mucosal cells or cell culture medium	23248
autologous olfactory mucosal cells	23255
cell culture medium	23293
Transplants	23320
fluoroscopic guidance	23368
correct needle placement	23400
-LRB- D -RRB- A blinded observer	23426
-LRB- D -RRB-	23426
A blinded observer	23430
outcome	23458
monthly intervals for 6 months	23469
monthly intervals	23469
6 months	23491
intervention	23506
Each test and statistical analysis method	23520
Each test	23520
statistical analysis method	23534
analysis	23596
the primary outcome measure	23606
objective quantification of forelimb	23638
objective quantification	23638
forelimb	23666
hindlimb temporal coordination	23675
computerized analysis of digitized kinematic data	23712
computerized analysis	23712
digitized kinematic data	23737
SSEP = somatosensory-evoked potential	23763
TMMEP = transcranial magnetic motor-evoked potential	23802
Figure 3 Digital recordings of locomotor activity	23857
Figure 3 Digital recordings	23857
Figure	23857
3 Digital recordings	23864
locomotor activity	23888
sine wave patterns	23929
forward and backward	23971
motion of the paws during walking on a treadmill	23992
motion	23992
the paws during walking on a treadmill	24002
the paws	24002
a treadmill	24029
this series of wave patterns	24045
this series	24045
wave patterns	24060
video recordings of Dog 8 in Supplementary Fig. 2	24092
video recordings	24092
Dog 8 in Supplementary Fig. 2	24112
Dog 8	24112
Supplementary Fig. 2	24121
the fore paw movement	24143
the dark and light green traces and the hind paw movement	24177
the dark and light green traces	24177
the hind paw movement	24213
the red and blue traces	24238
The generation of the sine wave pattern	24263
The generation	24263
the sine wave pattern	24281
in A	24318
the correspondence between forward and backward motion of the paw	24337
the correspondence between forward	24337
the correspondence	24337
backward motion of the paw	24376
backward motion	24376
the paw	24395
treadmill walking -LRB- the oval shape on the image in A -RRB-	24410
treadmill walking	24410
the oval shape on the image in A	24429
the oval shape	24429
the image in A	24447
the image	24447
A	24460
the wave pattern	24467
Temporal coordination between forelimb and hindlimb motion	24485
Temporal coordination	24485
forelimb and hindlimb motion	24515
a MATLAB script	24567
the time interval	24596
the peaks	24622
the ` sine wave ' patterns	24635
red lines between the curves in B , C and D	24661
red lines	24661
the curves in B , C and D	24679
the curves	24679
B , C and D	24693
the furthest extent of each step	24723
the furthest extent	24723
each step	24746
each limb	24759
Pre-transplantation	24770
Dog 8 -LRB- A -RRB-	24793
there	24804
only occasional stepping movements in the hindlimb	24814
only occasional	24814
movements in the hindlimb	24839
movements	24839
the hindlimb	24852
this	24869
the very high ` coordination score ' -LRB- here = 2.71 -RRB-	24890
the very high ` coordination score '	24890
= 2.71	24931
a summation of the ` lag ' between corresponding forelimb and hindlimb movements	24949
a summation	24949
the ` lag ' between corresponding forelimb and hindlimb movements	24964
the ` lag '	24964
corresponding forelimb and hindlimb movements	24982
1 month -LRB- B -RRB- and 6 months -LRB- C -RRB-	25032
1 month -LRB- B -RRB-	25032
1 month	25032
B	25041
6 months -LRB- C -RRB-	25048
C	25058
the same dog	25062
more regular hindlimb stepping	25081
more regular hindlimb	25081
overall coordination	25117
there	25165
an increasing ` lag ' time	25185
corresponding fore paw and hind paw placement	25218
the recording period	25271
the ` coordination score ' is 1.21 in B and 0.78 in C	25293
the ` coordination score ' is 1.21 in B	25293
the ` coordination score '	25293
1.21 in B	25321
1.21	25321
B	25329
0.78 in C	25335
0.78	25335
C	25343
D	25350
Dog 30	25353
a return	25372
near-normal coordination	25384
fore paw and hind paw placement	25417
transplantation of olfactory mucosal cells 6 months	25455
transplantation	25455
olfactory mucosal cells	25474
6 months	25498
the ` coordination score ' = 0.26	25519
the ` coordination score '	25519
= 0.26	25544
this panel	25556
there	25568
prolonged periods	25578
regularity	25599
the time interval	25613
fore paw and hind paw placement	25639
normal dogs	25685
periods in which coordination between limb girdles is lost	25716
periods	25716
coordination between limb girdles	25733
coordination	25733
limb girdles	25754
Figure 4 Analysis	25777
effect	25798
intraspinal injection	25808
olfactory mucosal cells -LRB- OMC , blue -RRB-	25833
olfactory mucosal cells	25833
OMC	25858
blue	25863
cell transport medium	25883
NC , red	25912
NC	25912
red	25916
measures of forelimb	25924
measures	25924
forelimb	25936
hindlimb coordination -LRB- A -RRB-	25945
hindlimb coordination	25945
A	25968
spinal cord long tract function -LRB- B -- E -RRB-	25975
spinal cord	25975
long tract function -LRB- B -- E -RRB-	25987
long tract function	25987
B -- E	26008
B	26008
E	26010
-LRB- A -RRB- Linear regression plot of fore	26014
-LRB- A -RRB- Linear regression plot	26014
-LRB- A -RRB- Linear regression	26014
A	26015
fore	26044
hind coordination scores	26049
the 6-month trial period -LRB- low scores indicate good performance -RRB-	26081
the 6-month trial period	26081
low scores	26107
good performance	26127
* The sum effect	26146
The sum effect	26147
olfactory mucosal cell transplantation	26165
the no-cell group	26218
the effects of time and baseline scores	26258
the effects	26258
time and baseline scores	26273
b	26323
= -0.455 ; P = 0.007	26325
= -0.455	26325
P = 0.007	26335
P	26335
0.007	26339
-LRB- B -RRB- Linear regression	26347
B	26348
plot	26369
lateral stability ratio scores	26377
the 6-month trial period	26415
low scores	26441
poor performance	26461
The scores	26480
the olfactory mucosal cell and no-cell groups -LRB- b = 0.049 ; P = 0.428 -RRB-	26514
the olfactory mucosal cell	26514
no-cell groups -LRB- b = 0.049 ; P = 0.428 -RRB-	26545
no-cell groups	26545
b = 0.049 ; P = 0.428	26561
b = 0.049	26561
b	26561
0.049	26565
P = 0.428	26572
P	26572
0.428	26576
A and B , solid lines	26587
linear relationships	26617
lines	26649
95 % confidence intervals	26664
-LRB- C -RRB- Latencies of transcranial magnetic motor-evoked potentials	26690
-LRB- C -RRB- Latencies	26690
C	26691
transcranial magnetic motor-evoked potentials	26707
and 6 months	26769
intervention	26788
individual dog size -LRB- each symbol represents a single individual -RRB-	26818
individual dog size	26818
each symbol	26839
a single individual	26862
There	26884
no difference	26894
recovery incidence	26911
Fisher exact test P = 1.00	26931
Fisher	26931
exact test P = 1.00	26938
exact test P	26938
1.00	26953
final latencies	26962
P	26979
= 0.544 , Mann -- Whitney test	26981
= 0.544	26981
Mann	26990
Whitney test	26995
the olfactory mucosal cell and no-cell groups	27017
-LRB- D -RRB- Latencies	27064
D	27065
recorded somatosensory-evoked potentials before and 6 months after intervention	27081
recorded somatosensory-evoked potentials	27081
and 6 months after intervention	27129
and 6 months	27129
intervention	27148
individual dog size -LRB- each symbol represents a single individual -RRB-	27174
individual dog size	27174
each symbol	27195
a single individual	27218
There	27240
no difference	27250
recovery incidence	27267
P = 1.00 , Fisher exact test	27287
P = 1.00	27287
P	27287
1.00	27291
Fisher exact test	27297
final latencies	27319
P	27336
= 0.788 , Mann -- Whitney test	27338
= 0.788	27338
Mann	27347
Whitney test	27352
the olfactory mucosal cell and no-cell groups	27374
C and D	27424
lines	27433
mean and SEM	27448
-LRB- E -RRB- Bladder compliance measures	27462
-LRB- E -RRB-	27462
Bladder compliance measures	27466
and 6 months	27510
intervention	27529
There	27543
no difference	27553
compliance between the olfactory mucosal cell and no-cell groups	27570
compliance	27570
the olfactory mucosal cell and no-cell groups	27589
the trial period	27642
b	27660
= -0.077 ; P = 0.852 ; multivariable regression analysis	27662
= -0.077	27662
P = 0.852	27672
P	27672
0.852	27676
multivariable regression analysis	27683
Bars	27719
mean	27733
lines	27739
SEM	27754
Eighty-five companion dogs	27760
severe spinal cord injury of at least 3 months ' duration	27792
severe spinal cord injury	27792
at least 3 months ' duration	27821
at least 3 months '	27821
eligibility for the study	27867
eligibility	27867
the study	27883
34	27898
randomized subjects -LRB- Fig. 1 -RRB-	27917
randomized subjects	27917
Fig. 1	27938
The characteristics of the dogs and their baseline scores	27947
The characteristics	27947
the dogs and their baseline scores	27970
the dogs	27970
their baseline scores	27983
Tables 1 and 2 ; 31	28019
the 34 dogs	28041
spinal cord injury	28062
a result	28084
acute intervertebral disc extrusion	28096
the most common cause of acute contusive spinal cord injury	28132
the most common cause	28132
acute contusive spinal cord injury	28157
dogs -LRB- Fluehmann et al. , 2006 -RRB-	28195
dogs	28195
Fluehmann	28201
et al. , 2006	28211
et al.	28211
2006	28219
The breeds	28226
this study	28249
those affected by acute intervertebral disc extrusion	28275
those	28275
acute intervertebral disc extrusion	28293
All patients when first presented for this study	28330
All patients	28330
first	28348
this study	28368
no volitional motor function or pain sensation	28383
the pelvic limbs -LRB- i.e. equivalent to ASIA grade ` A ' in humans -RRB-	28433
the pelvic limbs	28433
i.e. equivalent to ASIA grade ` A ' in humans	28451
i.e.	28451
equivalent to ASIA grade ` A ' in humans	28456
ASIA grade	28470
` A	28481
humans	28488
Dogs	28497
intraspinal injections	28537
either autologous olfactory mucosal cells or cell transport medium	28563
autologous olfactory mucosal cells	28570
cell transport medium	28608
a 2:1 ratio -LRB- Fig. 2 -RRB-	28639
a 2:1 ratio	28639
Fig. 2	28652
All dogs	28661
the study	28683
n = 34 : olfactory mucosal cell = 23 , no cell group	28694
n = 34 : olfactory mucosal cell = 23	28694
n = 34	28694
n	28694
34	28698
olfactory mucosal cell = 23	28702
olfactory mucosal cell	28702
23	28727
no cell group	28731
11	28747
the final results , which therefore constitutes an intention-to-treat analysis	28768
the final results	28768
an intention-to-treat analysis	28815
Four dogs	28847
the study	28869
urinary tract infection	28880
n = 2	28905
n =	28905
2	28909
intravascular coagulation : n = 1 ; intrathoracic haemorrhage : n = 1	28935
intravascular coagulation	28935
n = 1	28962
n	28962
1	28966
intrathoracic haemorrhage	28969
n = 1	28996
n	28996
1	29000
postmortem examination in each case	29008
postmortem examination	29008
each case	29034
no evidence to link death to the intervention	29054
death	29074
the intervention	29083
Transient -LRB- < 48 h -RRB- mild side-effects	29101
Transient	29101
< 48 h	29112
<	29112
48 h	29113
mild side-effects	29119
mild spinal pain : n = 2 ; suspected ileus : n = 2	29138
mild	29138
spinal pain : n = 2 ;	29143
spinal pain	29143
n = 2	29156
n	29156
2	29160
ileus : n = 2	29173
ileus	29173
n = 2	29180
n	29180
2	29184
four dogs	29199
intraspinal transplantation	29215
there	29248
no evidence of long-term detrimental effects in any dog	29258
no evidence	29258
long-term detrimental effects in any dog	29273
long-term detrimental effects	29273
any dog	29306
Adverse effects	29315
Table 3	29349
the pre-specified primary outcome measure , fore -- hind coordination	29362
the pre-specified primary outcome measure	29362
fore -- hind coordination	29405
fore	29405
hind coordination	29410
there	29429
a change in score	29439
a change	29439
score	29451
the course	29464
the study	29478
a mean	29493
1.35 -LRB- SD = 0.71 -RRB- to 0.95 -LRB- SD = 0.74 -RRB-	29503
1.35 -LRB- SD = 0.71 -RRB-	29503
1.35	29503
SD	29509
0.71	29514
0.95 -LRB- SD = 0.74 -RRB-	29523
0.95	29523
SD	29529
0.74	29534
log units between the baseline	29540
log units	29540
the baseline	29558
6-month time point in the olfactory mucosal cell transplant recipients	29575
6-month time point	29575
the olfactory mucosal cell transplant recipients	29597
a change	29661
1.53 -LRB- SD = 0.94 -RRB- to 1.86 -LRB- SD = 0.89 -RRB- in the no-cell group	29675
1.53 -LRB- SD = 0.94 -RRB-	29675
1.53	29675
SD	29681
0.94	29686
1.86 -LRB- SD = 0.89 -RRB- in the no-cell group	29695
1.86 -LRB- SD = 0.89 -RRB-	29695
1.86	29695
SD = 0.89	29701
SD	29701
the no-cell group	29715
The effect size	29734
the distribution-based description of the minimal important clinical difference	29776
the distribution-based description	29776
the minimal important clinical difference	29814
0.955	29862
a ` large effect ' -LRB- Wyrwich and Wolinshy , 2000 -RRB-	29892
a ` large effect '	29892
Wyrwich and Wolinshy	29910
2000	29932
an appreciable clinical benefit in human patients	29979
an appreciable clinical benefit	29979
human patients	30014
The effect size	30030
more detail in Fig. 3	30064
more detail	30064
Fig. 3	30079
a video recording	30093
the online Supplementary material	30114
the motion analysis graphs and corresponding sequential video recordings	30175
The transplant effect	30249
more detail	30291
multivariable regression analysis	30309
baseline values	30360
inclusion as a covariate	30379
inclusion	30379
a covariate	30392
a highly significant effect	30422
olfactory mucosal cell transplantation	30453
hindlimb activity and fore	30495
hind coordination	30522
regression coefficient	30541
-LSB- b -RSB- = -0.455 -LSB- 95 % confidence interval -LRB- CI -RRB-	30564
= -0.455	30568
95 % confidence interval -LRB- CI -RRB-	30578
95 % confidence interval	30578
CI	30603
-0.784 to -0.126 -RSB-	30608
-0.784	30608
-0.126 -RSB-	30618
P = 0.007	30627
P	30627
0.007	30631
Fig. 4	30638
Fig.	30638
4	30643
Pre-intervention score -LRB- covariate -RRB-	30647
Pre-intervention score	30647
covariate	30671
a significant influence	30686
b = 0.684 -LRB- 95 % CI : 0.492 to 0.877 -RRB-	30711
b	30711
= 0.684 -LRB- 95 % CI : 0.492 to 0.877 -RRB-	30713
= 0.684	30713
95 % CI : 0.492 to 0.877	30722
95 % CI	30722
0.492 to 0.877	30730
P50 .001 -RSB- on fore	30747
P50 .001 -RSB-	30747
fore	30759
hind coordination outcome but time	30765
hind coordination outcome	30765
time	30795
intervention	30806
the test population	30823
a whole	30846
not -LSB- b = 0.012 -LRB- 95 % CI : -0.021 to 0.046 -RRB-	30859
not -LSB- b	30859
0.012	30868
95 % CI : -0.021 to 0.046	30875
95 % CI	30875
-0.021 to 0.046	30883
P = 0.474	30901
P	30901
0.474	30905
Dogs in the olfactory mucosal cell transplantation group	30913
Dogs	30913
the olfactory mucosal cell transplantation group	30921
a cell preparation	30989
6.24 -LSB- ± standard error -LRB- SE -RRB- = 0.39	31019
6.24 -LSB- ± standard error -LRB- SE -RRB-	31019
6.24 -LSB- ± standard error	31019
SE	31042
0.39	31048
106 cells	31056
total , enriched in p75 + cells to a mean purity	31069
p75 + cells to a mean	31088
p75 + cells	31088
a mean	31103
49.4 % -LRB- ± SE = 6.8 -RRB-	31120
49.4 %	31120
± SE	31127
6.8	31133
the cell preparation	31150
3.20 -LRB- ± SE = 0.49 -RRB-	31187
3.20	31187
± SE	31193
0.49	31199
10 ^ 6 p75	31207
10	31207
6 p75	31210
cells -LRB- assumed to be olfactory ensheathing cells -RRB- , 2.82	31218
cells -LRB- assumed to be olfactory ensheathing cells -RRB-	31218
cells	31218
olfactory ensheathing cells	31239
2.82	31269
± SE	31275
0.49	31281
10 ^	31289
6 fibronectinexpressing cells	31292
likely to be fibroblasts derived from the sub-mucosa	31323
fibroblasts derived from the sub-mucosa	31336
fibroblasts	31336
the sub-mucosa	31361
0.21 -LRB- ± SE = 0.06 -RRB- x 106 unidentified cells	31382
0.21 -LRB- ± SE = 0.06 -RRB-	31382
0.21	31382
± SE	31388
0.06	31394
106 unidentified cells	31402
Supplementary Fig. 3	31426
cell transplant recipients	31452
there	31480
no significant relationship between forelimb	31490
no significant relationship	31490
forelimb	31526
hindlimb coordination	31535
the proportion	31561
p75 + cells	31579
the transplant	31608
each dog	31623
transplanted	31650
b = -0.002 -LRB- 95 % CI : -0.009 to 0.005 -RRB-	31664
b	31664
-0.002	31668
95 % CI : -0.009 to 0.005	31676
95 % CI	31676
-0.009 to 0.005	31684
P = 0.52 -RSB-	31702
P	31702
0.52 -RSB-	31706
We	31713
a series	31730
secondary outcome measures	31742
the effect	31789
the intervention on sensory and motor spinal cord long tract function	31803
the intervention on sensory	31803
the intervention	31803
sensory	31823
motor spinal cord long tract function	31835
motor spinal cord	31835
long tract function	31853
hindlimb lateral stability -LRB- Hamilton et al. , 2008 -RRB-	31878
hindlimb lateral stability	31878
Hamilton	31906
et al. , 2008	31915
et al.	31915
2008	31923
a measure of hindlimb coordination with centre of gravity	31930
a measure	31930
hindlimb coordination with centre of gravity	31943
hindlimb coordination	31943
centre of gravity	31970
centre	31970
gravity	31980
no significant effect	31989
multivariable regression analysis	32018
olfactory mucosal cell transplantation	32104
b = 0.049 -LRB- 95 % CI : -0.072 to 0.170 -RRB-	32144
b = 0.049	32144
b	32144
0.049	32148
95 % CI : -0.072 to 0.170	32155
95 % CI	32155
-0.072 to 0.170	32163
P = 0.428 -RSB- , but both time -LSB- b = -0.018	32181
P = 0.428 -RSB-	32181
P	32181
0.428 -RSB-	32185
both time -LSB- b = -0.018	32197
both time -LSB- b	32197
both time -LSB-	32197
-0.018	32212
95 % CI : -0.034 to -0.002	32220
95 % CI	32220
-0.034 to -0.002	32228
P = 0.029	32247
P	32247
0.029	32251
pre-intervention score -LSB- b = 0.386 -LRB- 95 % CI : 0.209 to 0.563 -RRB-	32262
pre-intervention score	32262
b = 0.386 -LRB- 95 % CI : 0.209 to 0.563 -RRB-	32286
b = 0.386	32286
b	32286
0.386	32290
95 % CI : 0.209 to 0.563	32297
95 %	32297
CI : 0.209 to 0.563	32301
CI	32301
0.209 to 0.563	32305
P50 .001 -RSB- had a significant effect	32322
P50 .001	32322
a significant effect	32335
Somatosensory-evoked potentials	32357
the scalp in 12 of the 34 dogs	32412
the scalp	32412
12 of the 34 dogs	32425
12	32425
the 34 dogs	32431
trial entry	32446
the latency of this response	32463
the latency	32463
this response	32478
mean latency reduction = 0.85 ms	32513
mean latency reduction = 0.85	32513
mean latency reduction	32513
ms	32543
the study period	32554
An additional two dogs regained	32572
An additional two dogs	32572
somatosensory	32604
potentials	32626
the end of the trial , of which one had received olfactory mucosal cells	32640
the end	32640
the trial , of which one had received olfactory mucosal cells	32651
the trial	32651
one	32671
olfactory mucosal cells	32688
Transcranial magnetic motorevoked potentials	32713
the tibialis cranialis muscle	32779
intervention in 13 dogs	32816
intervention	32816
13 dogs	32832
An additional three dogs	32841
this response	32875
the 6-month trial period , two of which had received olfactory mucosal cells	32896
the 6-month trial period	32896
olfactory mucosal cells	32948
There	32973
no difference	32983
incidence	33000
recovery of somatosensory-evoked potentials	33013
recovery	33013
somatosensory-evoked potentials	33025
transcranial magnetic motor-evoked potentials	33060
groups -LRB- Fisher exact test , P = 1.00 for each -RRB-	33114
groups	33114
Fisher exact test , P = 1.00 for each	33122
Fisher exact test	33122
P = 1.00 for each	33141
P = 1.00	33141
P	33141
1.00	33145
each	33154
Urinary bladder compliance	33161
a measure	33189
CNS modulation of bladder activity -LRB- Biering-Sørensen et al. , 2008 -RRB-	33202
CNS modulation	33202
bladder activity -LRB- Biering-Sørensen et al. , 2008 -RRB-	33220
bladder activity	33220
Biering-Sørensen	33238
et al. , 2008	33255
et al.	33255
2008	33263
31 dogs throughout the trial	33288
31 dogs	33288
the trial	33307
olfactory mucosal cell	33344
no-cell groups -LSB- b = -0.077 -LRB- 95 % CI : -0.891 to 0.736 -RRB-	33371
no-cell groups	33371
b = -0.077 -LRB- 95 % CI : -0.891 to 0.736 -RRB-	33387
b = -0.077	33387
b	33387
-0.077	33391
95 % CI : -0.891 to 0.736	33399
95 % CI	33399
-0.891 to 0.736	33407
P = 0.852	33425
P	33425
0.852	33429
analysis by multivariable regression	33436
analysis	33436
multivariable regression	33448
Discussion The results of this study	33500
Discussion The results	33500
Discussion	33500
The results	33511
this study	33526
injection of olfactory mucosa-derived cells in a blinded randomized trial	33561
injection	33561
olfactory mucosa-derived cells in a blinded randomized trial	33574
olfactory mucosa-derived cells	33574
a blinded randomized trial	33608
improvements in locomotor outcome	33654
improvements	33654
locomotor outcome	33670
chronic clinical spinal cord injury	33691
This result	33728
a substantial advance	33743
previously available laboratory data	33768
intraspinal olfactory cell transplantation	33815
it	33866
the beneficial effects	33886
clinical cases	33958
the ` noise '	33983
other uncontrolled variables	33998
precise character of the injury	34036
precise character	34036
the injury	34057
an effect	34075
the effects	34124
cases	34166
chronic spinal cord injury	34177
a plateau of recovery	34232
a plateau	34232
recovery	34245
some of the dogs	34256
some	34256
the dogs	34264
412 months	34297
sufficient magnitude	34322
locomotor patterns	34353
a clinically useful effect -LRB- Supplementary Fig. 2 -RRB-	34377
a clinically useful effect	34377
Supplementary Fig. 2	34405
Supplementary Fig.	34405
2	34424
It	34428
experimental animals	34451
interventions in chronic spinal cord injury	34477
interventions	34477
chronic spinal cord injury	34494
a detectable benefit	34529
the numerous obstacles to regeneration	34561
the numerous obstacles	34561
regeneration	34587
functional recovery at this stage -LRB- Kadoya et al. , 2009 -RRB-	34604
functional recovery	34604
this stage -LRB- Kadoya et al. , 2009 -RRB-	34627
this stage	34627
Kadoya	34639
et al. , 2009	34646
et al.	34646
2009	34654
these data	34673
improvement in spinal cord connectivity	34697
improvement	34697
spinal cord connectivity	34712
human patients	34772
they	34790
a similar intervention , such as those enrolled in the recently reported Phase	34811
a similar intervention	34811
those enrolled in the recently reported Phase	34843
those	34843
the recently reported Phase	34861
I	34889
human trials	34891
Lima	34905
et al. , 2008 ; 2010 ; Mackay-Sim et al. , 2008 ; Chhandra et al. , 2009	34910
et al.	34910
2008 ; 2010 ; Mackay-Sim et al. , 2008 ; Chhandra et al.	34918
2008 ; 2010	34918
2008	34918
2010	34924
Mackay-Sim et al. , 2008	34930
Mackay-Sim	34930
et al. , 2008	34941
et al.	34941
2008	34949
Chhandra et al.	34955
Chhandra	34955
et al.	34964
2009	34972
it	34988
that improvement on our primary outcome measure	35017
that improvement	35017
our primary outcome measure	35037
a composite	35068
increase in spinal stepping activity	35088
increase	35088
spinal stepping activity	35100
a non-stepping dog	35129
forelimbs and hindlimbs	35166
increase in hindlimb step coordination with the forelimbs	35195
increase	35195
hindlimb step coordination with the forelimbs	35207
hindlimb step coordination	35207
the forelimbs	35239
restoration of brain control	35284
restoration	35284
brain control	35299
hindlimb motion	35318
Our secondary outcome measures	35335
insight	35391
mechanisms	35404
olfactory mucosal cell transplantation	35424
its effects	35480
experimental studies on focal lesions in rodents	35496
experimental studies	35496
focal lesions in rodents	35520
focal lesions	35520
rodents	35537
there	35546
strong evidence	35555
olfactory ensheathing cells	35576
regeneration	35616
long tract -LRB- e.g. pyramidal tract -RRB- axons -LRB- Li et al. , 1998 -RRB-	35632
long tract -LRB- e.g. pyramidal tract -RRB- axons	35632
e.g. pyramidal tract	35644
e.g.	35644
pyramidal tract	35649
Li	35673
et al. , 1998	35676
et al.	35676
1998	35684
olfactory	35695
cell-mediated functional improvement in complete transection models	35717
cell-mediated functional improvement	35717
complete transection models	35757
serotonergic fibre regeneration -LRB- Ramon-Cueto et al. , 2000 -RRB-	35817
serotonergic fibre regeneration	35817
Ramon-Cueto	35850
et al. , 2000	35862
et al.	35862
2000	35870
The improved forelimb	35877
hindlimb coordination we observed	35899
hindlimb coordination	35899
we	35921
enhanced communication across the damaged region of spinal cord	35941
enhanced communication	35941
the damaged region of spinal cord	35971
the damaged region	35971
spinal cord	35993
long-range axon regeneration	36042
our data	36081
this	36112
these dogs -- most notably the lack of improvement	36142
these dogs	36142
the lack of improvement	36168
the lack	36168
improvement	36180
any	36195
our measures	36202
long tract function	36218
i.e.	36239
lateral stability	36244
somatosensory-evoked potential	36263
transcranial magnetic motorevoked potential	36295
urodynamics	36343
the concomitant improvement in fore -- hind coordination	36364
the concomitant improvement in fore	36364
the concomitant improvement	36364
fore	36395
hind coordination	36400
plastic changes in propriospinal connections	36428
plastic changes	36428
propriospinal connections	36447
an explanation for improvement in fore	36481
an explanation	36481
improvement in fore	36500
improvement	36500
fore	36515
hind coordination that is more consistent with the data	36520
hind coordination	36520
the data	36567
Such an effect	36577
many processes including	36610
many processes	36610
, local axon sprouting	36654
, local axon	36654
Many other	36678
previously documented properties of olfactory ensheathing cells	36689
previously documented properties	36689
olfactory ensheathing cells	36725
modulation	36780
immune responses -LRB- Arnold and Hagg , 2011 ; Chuah et al. , 2011 -RRB-	36794
immune responses	36794
Arnold and Hagg , 2011 ; Chuah et al. , 2011	36812
Arnold and Hagg	36812
2011 ; Chuah et al.	36829
2011	36829
Chuah et al.	36835
Chuah	36835
et al.	36841
2011	36849
provision	36856
neurotrophic factors -LRB- Chiu et al. , 2009 -RRB- , remyelination of	36869
neurotrophic factors -LRB- Chiu et al. , 2009 -RRB-	36869
neurotrophic factors	36869
Chiu	36891
et al. , 2009	36896
et al.	36896
2009	36904
remyelination of	36911
remyelination	36911
axons	36941
Franklin	36948
et al. , 1996 ; Sasaki et al. , 2011	36957
et al.	36957
1996 ; Sasaki et al.	36965
1996	36965
Sasaki et al.	36971
Sasaki	36971
et al.	36978
2011	36986
modulation of glia and neuronal function -LRB- Chuah et al. , 2011 -RRB-	36995
modulation	36995
glia and neuronal function -LRB- Chuah et al. , 2011 -RRB-	37009
glia and neuronal function	37009
Chuah	37037
et al. , 2011	37043
et al.	37043
2011	37051
It	37058
the effects of the olfactory mucosal cell transplant	37083
the effects	37083
the olfactory mucosal cell transplant	37098
effects	37164
the olfactory ensheathing cell component of the transplanted population	37184
the olfactory ensheathing cell component	37184
the transplanted population	37228
Our data	37257
a clear and strong overall effect of olfactory mucosal cell transplants	37271
a clear and strong overall effect	37271
olfactory mucosal cell transplants	37308
extent of recovery	37348
extent	37348
recovery	37358
the total proportion of p75	37396
the total proportion	37396
p75	37420
olfactory ensheathing cells contained within the transplant population	37426
olfactory ensheathing cells	37426
the transplant population	37471
a similar observation	37513
transplantation of olfactory mucosa-derived cells	37560
transplantation	37560
olfactory mucosa-derived cells	37579
rat models of spinal cord injury -LRB- Yamamoto et al. , 2009 -RRB-	37613
rat models	37613
spinal cord injury -LRB- Yamamoto et al. , 2009 -RRB-	37627
spinal cord injury	37627
Yamamoto	37647
et al. , 2009	37656
et al.	37656
2009	37664
This finding	37671
the possibility	37701
the effect	37722
a threshold number of olfactory ensheathing cells	37754
a threshold number	37754
olfactory ensheathing cells	37776
the population , which might be quite low	37811
the population	37811
it	37867
the precise type of cells in the transplant	37889
the precise type	37889
cells in the transplant	37909
cells	37909
the transplant	37918
the success of mucosal-derived transplants	37952
the success	37952
mucosal-derived transplants	37967
It	37996
their effects	38031
a result	38054
local axon sprouting -LRB- Yamamoto et al. , 2009 -RRB-	38066
local axon sprouting	38066
local axon	38066
Yamamoto	38088
et al. , 2009	38097
et al.	38097
2009	38105
the long-range axon regeneration	38123
formation	38172
bridges ' across the lesion site	38186
bridges '	38186
the lesion site	38202
other types of olfactory cell transplants -LRB- Raisman and Li , 2007 -RRB-	38248
other types	38248
olfactory cell transplants -LRB- Raisman and Li , 2007 -RRB-	38263
olfactory cell transplants	38263
Raisman and Li , 2007	38291
Raisman	38291
Li , 2007	38303
Li	38303
2007	38307
This explanation	38314
the observation	38353
the effect in our study	38374
the effect	38374
our study	38388
the intraspinal connectivity -LRB- i.e. acting at a local level -RRB-	38422
the intraspinal connectivity	38422
i.e. acting at a local level	38452
i.e.	38452
a local level	38467
communication between spinal locomotor centres and the brain	38494
communication	38494
spinal locomotor centres and the brain	38516
spinal locomotor centres	38516
the brain	38545
the precise relationship between transplanted olfactory mucosal cell	38579
the precise relationship	38579
transplanted olfactory mucosal cell	38612
functional outcome	38652
it	38672
the survival of transplanted cells within host tissue	38707
the survival	38707
transplanted cells within host tissue	38723
transplanted cells	38723
host tissue	38749
A percutaneous cell transplantation technique	38762
this study	38820
blinded comparison	38853
intraspinal injections	38880
cells	38932
Percutaneous delivery of cells	38939
Percutaneous delivery	38939
cells	38964
the need for a sham surgical procedure in the control animals	38977
the need	38977
a sham surgical procedure in the control animals	38990
a sham surgical procedure	38990
the control animals	39019
blinding purposes	39051
similar avoidance	39075
the ethical problems	39096
sham	39133
neurosurgical procedures -LRB- Galpern et al. , 2012 -RRB-	39138
neurosurgical procedures	39138
Galpern	39164
et al. , 2012	39172
et al.	39172
2012	39180
value during translation	39203
value	39203
translation	39216
human patients	39233
Our previous intraspinal cell transplantation technique	39249
Jeffery	39306
et al. , 2005	39314
et al.	39314
2005	39322
surgical exposure of the spinal cord	39332
surgical exposure	39332
the spinal cord	39353
accurate needle placement	39377
the spinal cord parenchyma	39408
cells	39486
their target site	39495
cerebrospinal fluid	39524
spinal puncture	39551
unequivocal evidence of needle bevel position within an intradural location	39576
unequivocal evidence	39576
needle bevel position within an intradural location	39600
needle bevel position	39600
an intradural location	39629
needle stability during injection	39657
needle stability	39657
injection	39681
the surrounding soft tissue , thus minimizing transplant leakage	39715
the surrounding soft tissue	39715
transplant leakage	39760
It	39780
no detrimental effects on the recipients	39832
no detrimental effects	39832
the recipients	39858
human medicine	39920
human patients with spinal cord injury	39939
human patients	39939
spinal cord injury	39959
introduction of a larger number of needles	39979
introduction	39979
a larger number of needles	39995
a larger number	39995
needles	40014
delivery of cells	40048
delivery	40048
cells	40060
the whole length of lesions	40069
the whole length	40069
lesions	40089
severe fracture luxations	40112
much greater relative size	40155
the lesions treated in the current study	40187
the lesions	40187
the current study	40210
A major reason for carrying out this study	40229
A major reason	40229
this study	40261
intraspinal transplantation of olfactory mucosal cell	40297
intraspinal transplantation	40297
olfactory mucosal cell	40328
an appropriate subject	40360
expeditious clinical efficacy trials in human patients with spinal cord injury	40387
expeditious clinical efficacy trials	40387
human patients with spinal cord injury	40427
human patients	40427
spinal cord injury	40447
Several groups throughout the world	40467
Several groups	40467
the world	40493
Phase	40528
I trials	40534
olfactory ensheathing cell transplantation	40546
spinal cord injury	40593
humans	40615
Lima	40623
et al. , 2006 , 2010 ; Mackay-Sim et al. , 2008 ; Chhabra et al. , 2009	40628
et al.	40628
2006 , 2010 ; Mackay-Sim et al. , 2008 ; Chhabra et al.	40636
2006 , 2010	40636
2006	40636
2010	40642
Mackay-Sim et al. , 2008	40648
Mackay-Sim	40648
et al. , 2008	40659
et al.	40659
2008	40667
Chhabra et al.	40673
Chhabra	40673
et al.	40681
2009	40689
the safety of this approach	40710
the safety	40710
this approach	40724
Efficacy testing	40739
much greater resources	40769
very careful consideration	40812
this study	40843
we	40864
olfactory mucosal cell transplantation	40884
communication	40932
the lesion	40953
recovery of ` automatic ' coordination between forelimbs and hindlimbs	40974
recovery	40974
` automatic ' coordination between forelimbs and hindlimbs	40986
` automatic ' coordination	40986
forelimbs and hindlimbs	41019
there	41044
few data to support improvement of spinal long tract function	41054
improvement of spinal long tract function	41074
improvement	41074
spinal long tract function	41089
Human spinal cord injury patients most	41117
Human spinal cord injury patients	41117
most	41151
recovery	41162
arm , bladder and sexual function -LRB- Anderson , 2004 -RRB-	41174
arm , bladder and sexual function	41174
Anderson	41208
2004	41218
spinal long tract function	41255
the brain	41297
lower motor	41327
neuron activity	41339
it	41376
olfactory mucosal cells	41416
human spinal cord injury patients	41445
clinically detectable effects	41504
it	41535
patients	41557
useful benefit	41583
their everyday lives	41601
Barnett and Riddell , 2007	41631
Barnett and Riddell	41631
2007	41652
that reason	41663
the main implication of our study	41676
the main implication	41676
our study	41700
it	41718
encouragement	41738
that olfactory mucosal cell transplants	41764
a sole treatment	41807
significant clinical benefit	41838
human spinal cord injury patients	41870
the effects we show here	41919
the effects	41919
we	41931
some worthwhile benefit	41956
the olfactory mucosal cell transplant	41983
part of a multimodal intervention	42032
part	42032
a multimodal intervention	42040
a future therapeutic strategy -LRB- Thuret et al. , 2006 -RRB-	42104
a future therapeutic strategy	42104
Thuret	42135
et al. , 2006	42142
et al.	42142
2006	42150
some previous human studies	42160
olfactory mucosal cell transplantation	42189
rehabilitation therapies -LRB- Chhabra et al. , 2009 ; Lima et al. , 2010 -RRB-	42252
rehabilitation therapies	42252
Chhabra	42278
et al. , 2009 ; Lima et al. , 2010	42286
et al.	42286
2009 ; Lima et al.	42294
2009	42294
Lima et al.	42300
Lima	42300
et al.	42305
2010	42313
themselves	42329
a beneficial effect on outcome	42349
a beneficial effect	42349
outcome	42372
interpretation of the origin of the observed effects	42402
interpretation	42402
the origin of the observed effects	42420
the origin	42420
the observed effects	42434
our current study	42459
the extent of physical exercise	42487
the extent	42487
physical exercise	42501
individuals	42534
there	42547
no systematic difference between groups of transplanted and control dogs	42557
no systematic difference	42557
groups of transplanted and control dogs	42590
groups	42590
transplanted and control dogs	42600
transplanted	42600
control dogs	42617
it	42635
an alternative explanation for our findings	42652
an alternative explanation	42652
our findings	42683
The information gained in this project	42697
The information	42697
this project	42723
the contributions	42748
study of spinal cord injury	42786
study	42786
spinal cord injury	42795
pet dogs	42817
a bridge between the laboratory and human clinic	42840
a bridge	42840
the laboratory and human clinic	42857
the laboratory	42857
human clinic	42876
promising therapies identified through previous research in rodents	42896
promising therapies	42896
previous research in rodents	42935
previous research	42935
rodents	42956
efficacy in this ` clinical model '	42984
efficacy	42984
this ` clinical model '	42996
human trials	43038
This translational aspect	43052
the provision	43096
relatively heterogeneous patient groups -LRB- similar to human patients -RRB-	43113
relatively heterogeneous patient groups	43113
human patients	43165
assessment	43204
electrophysiological testing	43221
quantitative functional neurological data	43272
The conclusion drawn from this approach	43315
The conclusion	43315
this approach	43341
olfactory mucosa-derived cell transplants	43363
substantial change	43417
function in a clinical spinal cord injury model	43439
function	43439
a clinical spinal cord injury model	43451
the effects	43497
local intraspinal circuitry	43529
long tract function	43572
us	43605
this intervention	43625
appreciable benefits in the treatment of human spinal cord injury	43669
appreciable benefits	43669
the treatment of human spinal cord injury	43693
the treatment	43693
human spinal cord injury	43710
a useful component of a multi-faceted approach	43762
a useful component	43762
a multi-faceted approach	43784
